ABSTRACT
This article on the topic of sterile and nonsterile repackaging is based on the content of United States Pharmacopeia 35-National Formulary 30 and how the respective official chapters of the publication relate to pharmacy compounding and practice. The article differentiates between commercial repackagers and pharmacists that repackage in their pharmacy for their patients. It also discusses the standards for packaging and the beyond-use dates that should be assigned.
Subject(s)
Drug Compounding , Drug Packaging , Drug Compounding/standards , Drug Packaging/standards , Humans , Sterilization , United States , Pharmacists , Pharmacopoeias as TopicABSTRACT
An international collaborative study was jointly organised by the World Health Organization (WHO) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) to establish the WHO 3rd International Standard (IS) for Prekallikrein activator (PKA) and European Pharmacopoeia (Ph. Eur.) PKA in albumin Biological Reference Preparation (BRP) batch 7. Twenty-six laboratories took part in the study to calibrate these replacement batches, as well as an additional reserve batch for the WHO IS, against the current WHO 2nd IS for PKA (02/168). Ph. Eur. PKA in albumin BRP batch 6 was also included to evaluate the continuity of the consecutive batches of BRP. The centrally calculated overall Huber's means based on the results from laboratories with at least two valid assays were 29.6 and 29.6 IU/ampoule for the candidate WHO 3rd IS (Sample A) and reserve batch (Sample B), and were 38.4 and 37.0 IU/vial for the current BRP batch 6 (Sample C) and the candidate BRP batch 7 (Sample D). The intra-laboratory variation expressed as coefficient of variation (CV) ranged between 1.4 and 16.6 %. The inter-laboratory variation expressed as CV based on Huber's means ranged between 4.4 and 5.4 %. The Huber's mean activity of Sample D against Sample C was 36.6 IU/vial with a CV of 1.7 %. These results confirm the good continuity of the consecutive batches of BRP. Based on the results of this study, it is recommended to establish Sample A as the WHO 3rd IS for PKA with an assigned potency of 30 IU/ampoule and Sample D as the Ph. Eur. PKA in albumin BRP batch 7 with an assigned potency of 37 IU/vial. Sample B is intended to be kept as a future reserve replacement WHO IS.
Subject(s)
Reference Standards , World Health Organization , Humans , Europe , International Cooperation , Albumins/standards , Pharmacopoeias as Topic/standardsABSTRACT
From sea shores to the abysses of the deep ocean, marine ecosystems have provided humanity with valuable medicinal resources. The use of marine organisms is discussed in ancient pharmacopoeias of different times and geographic regions and is still deeply rooted in traditional medicine. Thanks to present-day, large-scale bioprospecting and rigorous screening for bioactive metabolites, the ocean is coming back as an untapped resource of natural compounds with therapeutic potential. This renewed interest in marine drugs is propelled by a burgeoning research field investigating the molecular mechanisms by which newly identified compounds intervene in the pathophysiology of human diseases. Of great clinical relevance are molecules endowed with anti-inflammatory and immunomodulatory properties with emerging applications in the management of chronic inflammatory disorders, autoimmune diseases, and cancer. Here, we review the historical development of marine pharmacology in the Eastern and Western worlds and describe the status of marine drug discovery. Finally, we discuss the importance of conducting sustainable exploitation of marine resources through biotechnology.
Subject(s)
Aquatic Organisms , Drug Discovery , Humans , Animals , Drug Discovery/methods , Biological Products/pharmacology , Biological Products/chemistry , Pharmacopoeias as Topic , Oceans and Seas , Immunomodulating Agents/pharmacology , Immunomodulating Agents/chemistry , Immunomodulating Agents/isolation & purification , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/chemistry , Immunologic Factors/pharmacology , Immunologic Factors/chemistryABSTRACT
Powder flow is one of the crucial factors affecting several pharmaceutical manufacturing processes. Problems due to insufficient powder flow reduce production process efficiency and cause suboptimum product quality. The U.S. Pharmacopoeia has specified four methods to evaluate the flowability of pharmaceutical powders, including angle of repose (AoR), compressibility index (CI) and Hausner ratio (HR), Flow through an orifice, and shear cell. Comparison within and between those methods with 21 powders (covering a wide range of flowability) was performed in this study. Strong correlation was observed between fixed base cone AoR, and fixed height cone AoR (R2 = 0.939). CI and HR values calculated from a tapped density tester (meeting USP standards), manual tapping, and Geopyc® correlated strongly (R2 > 0.9). AoR, CI/HR, minimum diameter for flowing through an orifice (dmin), and shear cell results generally correlate strongly for materials with flowability worse than Avicel® PH102. Both shear cell and CI/HR methods can reliably distinguish powders exhibiting poor flow. For materials with good flow, the ability to distinguish powders follows the order of AoR ≈ CI/HR > shear cell > dmin. The systematic comparison of the four common methods provides useful information to guide the selection of methods for future powder flow characterization. Given the limitations observed in all four methods, we recommend that multiple techniques should be used, when possible, to more holistically characterize the flowability of a wide range of powders.
Subject(s)
Powders , Powders/chemistry , Particle Size , Technology, Pharmaceutical/methods , Drug Compounding/methods , Pharmacopoeias as Topic , Excipients/chemistryABSTRACT
In the execution of its legislated responsibilities, the United States Food and Drug Administration commonly refers to standard test methods detailed in the United States Pharmacopeia (USP). Microbiological test methods (contained in general chapters) are listed in chapters <51> to <80> with details regarded as enforceable where referenced as a test method. USP <61> "Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests" is a globally harmonized chapter that has been successfully employed for the enumeration of microorganisms recoverable from nonsterile finished drug products. The content of USP <61> is not always scientifically principled nor emphatically understood by all pharmaceutical microbiologists. Consequently, misunderstanding and misapplication of USP <61> may result in analyses and assessments of microbiological quality that are flawed or erroneous. In this article, clarification is provided to assist the pharmaceutical microbiologist in the appropriate and intended use of USP <61>, including provision of details not always commonly known or understood.
Subject(s)
Drug Contamination , Pharmacopoeias as Topic , Pharmacopoeias as Topic/standards , Drug Contamination/prevention & control , United States , United States Food and Drug Administration/standards , Microbiological Techniques/standards , Microbiological Techniques/methods , Colony Count, Microbial/standards , Pharmaceutical Preparations/standards , Pharmaceutical Preparations/analysisABSTRACT
RATIONALE: Perillae Fructus (PF) is a common traditional Chinese medicine (TCM) for the treatment of asthma. It has not been effectively characterized by rosmarinic acid (RosA), which is currently designed as the sole quality indicator in the Chinese Pharmacopoeia. METHODS: This study introduced a database-aided ultrahigh-performance liquid chromatography equipped with quadrupole-Exactive-Orbitrap mass spectrometry (UHPLC/Q-Exactive-Orbitrap MS/MS) technology to putatively identify the compounds in PF, followed by literature research, quantum chemical calculation, and molecular docking to screen potential quality markers (Q-markers) of PF. RESULTS: A total of 27 compounds were putatively identified, 16 of which had not been previously found from PF. In particular, matrine, scopolamine, and RosA showed relatively high levels of content, stability, and drug-likeness. They exhibited interactions with the asthma-related target and demonstrated the TCM properties of PF. CONCLUSIONS: The database-aided UHPLC/Q-Exactive-Orbitrap MS/MS can identify at least 27 compounds in PF. Of these, 16 compounds are unexpected, and three compounds (matrine, scopolamine, and RosA) should be considered anticounterfeiting pharmacopoeia Q-markers of PF.
Subject(s)
Drugs, Chinese Herbal , Tandem Mass Spectrometry , Chromatography, High Pressure Liquid/methods , Tandem Mass Spectrometry/methods , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/analysis , Molecular Docking Simulation , Pharmacopoeias as Topic , Fruit/chemistry , Scopolamine/analysis , Depsides/analysis , Depsides/chemistryABSTRACT
PURPOSE: A pharmacopoeia is a compendium of guidelines and criteria for drug quality. It was established by a national or regional entity and has legal significance. This applies to administration of drugs in a particular nation or region. METHOD: In this study, the differences and similarities of microbiological acceptance criteria, specifications for microbial enumeration of herbal drugs and herbal drug preparations in 14 national and international pharmacopeias were investigated. RESULTS: It was found that 12 pharmacopeias have given separate microbial limits for total aerobic microbial count (TAMC) and total yeast and mold count (TYMC), and a list of specified microorganisms for which acceptance criteria are defined. However, similarities were noticed in Ph.Eur, Ph. Helv and, BP. Salmonella, and Escherichia coli are the most common pathogens specified for herbal preparations in which boiling water is added prior to use and for internal use in all Pharmacopoeias because they serve as indicators of potential contamination. CONCLUSION: From this study, it can be concluded that the differences in microbial limit tests and their acceptance criteria as specified in the various pharmacopoeias need to be harmonized. It will become a more convenient option for global drug manufacturers to import/export herbal drugs, and this would also eliminate the burden of performing various analytical methods and comply with different microbial acceptance criteria set by various pharmacopoeias. The comparative data obtained from this study will be used to develop strategies for revisions of pharmacopoeias in a harmonized manner with respect to microbiological acceptance criteria, specifications for microbial enumeration of herbal drugs and herbal drug preparations.
Subject(s)
Drug Contamination , Pharmacopoeias as Topic , Plant Preparations , Plant Preparations/standards , Drug Contamination/prevention & control , Pharmacopoeias as Topic/standards , Colony Count, Microbial , Quality Control , HumansABSTRACT
The dissolution testing method described in the United States Pharmacopeia (USP) Chapter ⟨711⟩ is widely used for assessing the release of active pharmaceutical ingredients from solid dosage forms. However, extensive use over the years has revealed certain issues, including high experimental intervariability observed in specific formulations and the settling of particles in the dead zone of the vessel. To address these concerns and gain a comprehensive understanding of the hydrodynamic conditions within the USP 2 apparatus, computational fluid dynamic simulations have been employed in this study. The base design employed in this study is the 900 mL USP 2 vessel along with a paddle stirrer at a 50 rpm rotational speed. Additionally, alternative stirrer designs, including the hydrofoil, pitched blade, and Rushton impeller, are investigated. A comparison is also made between a flat-bottom tank and the USP round-bottom vessel of the same volume and diameter. Furthermore, this work examines the impact of various parameters, such as clearance distance (distance between the bottom of the impeller and bottom of the vessel), number of impeller blades, impeller diameter, and impeller attachment angle. The volume-average shear rate (Stv), fluid velocity (Utv), and energy dissipation rates (ϵtv) represent the key properties evaluated in this study. Comparing the USP2 design and systems with the same stirrer but flat-bottom vessel reveals more homogeneous mixing compared to the USP2 design. Analyzing fluid flow streamlines in different designs demonstrates that hydrofoil stirrers generate more suspension or upward movement of fluid compared to paddle stirrers. Therefore, when impellers are of a similar size, hydrofoil designs generate higher fluid velocities in the coning area. Furthermore, the angle of blade attachment to the hub influences the fluid velocity in the coning area in a way that the 60° angle design generates more suspension than the 45° angle design. The findings indicate that the paddle stirrer design leads to a heterogeneous shear rate and velocity distributions within the vessel compared with the other designs, suggesting suboptimal performance. These insights provide valuable guidance for the development of improved in vitro dissolution testing devices, emphasizing the importance of optimized design considerations to minimize hydrodynamic variability, enhance dissolution characterization, and reduce variability in dissolution test results. Ultimately, such advancements hold potential for improving in vitro-in vivo correlations in drug development.
Subject(s)
Hydrodynamics , Solubility , Drug Liberation , Chemistry, Pharmaceutical/methods , Pharmacopoeias as Topic , Computer Simulation , Equipment Design , Drug Compounding/methods , United StatesABSTRACT
For a solid understanding of drug characteristics, in vitro measurement of the intrinsic dissolution rate is important. Hydrodynamics are often emphasized as the decisive parameter influencing the dissolution. In this study, experiments and computational fluid dynamic (CFD) simulations showed that the mixing behavior in the rotating disc apparatus causes an inhomogeneous flow field and a systematic error in the calculation of the intrinsic dissolution rate. This error is affected by both the experimental time and the velocity. Due to the rotational movement around the tablet center, commonly utilized in pharmacopeia methods, a broad variance is present with regard to the impact of fluid velocity on individual particles of the specimen surface. As this is significantly reduced in the case of uniform overflow, the flow channel is recommended for investigating the dissolution behavior. It is shown that rotating disc measurements can be compared with flow channel measurements after adjusting the measured data for the rotating disc based on a proposed, representative Reynolds number and a suggested apparatus-dependent correction factor. Additionally, modeling the apparatus-independent intrinsic dissolution rate for different temperatures in the rotating disc apparatus is possible using the adapted Levich's equation.
Subject(s)
Hydrodynamics , Solubility , Tablets/chemistry , Drug Liberation , Pharmacopoeias as Topic , Computer Simulation , Chemistry, Pharmaceutical/methods , TemperatureABSTRACT
The epidemic prompted by COVID-19 continues to spread, causing a great risk to the general population's safety and health. There are still no drugs capable of curing it. Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are the two other diseases caused by coronaviruses. Traditional Chinese Medicine (TCM) showed benefits in treating SARS and MERS by preventing the disease early, substantially mitigating symptoms, shortening the treatment period, and minimizing risks and adverse reactions caused by hormone therapy. Although several vaccines have been developed and are being used for the treatment of COVID-19, existing vaccines cannot provide complete protection against the virus due to the rapid evolution and mutation of the virus, as mutated viral epitopes evade the vaccine's target and decrease the efficacy of vaccines. Thus, there is a need to develop alternative options. TCM has demonstrated positive effects in the treatment of COVID-19. Previous research studies on TCM showed broad-spectrum antiviral activity, offering a range of possibilities for their potential use against COVID-19. This study shed some light on common TCM used for SARS and MERS outbreaks and their effective use for COVID-19 management. This study provides new insights into COVID-19 drug discovery.
Subject(s)
Antiviral Agents , COVID-19 Drug Treatment , COVID-19 , Drugs, Chinese Herbal , Medicine, Chinese Traditional , SARS-CoV-2 , Humans , Medicine, Chinese Traditional/methods , Antiviral Agents/therapeutic use , Antiviral Agents/pharmacology , Drugs, Chinese Herbal/therapeutic use , Drugs, Chinese Herbal/pharmacology , SARS-CoV-2/drug effects , Pharmacopoeias as TopicABSTRACT
Gentianae Radix, an herbal medicine, has been used as a gastrointestinal drug in Japan. In the Japanese Pharmacopoeia 18th Revision, the sublimation test is specified as an identification test for Gentianae Radix. The compound obtained in this sublimation test was believed to be gentisin, a xanthone family compound. However, the compound we identified using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and 1H- and 13C-NMR was 5-(hydroxymethyl)furfural (5-HMF). The same compound was found to be a sublimate of Gentianae Scabrae Radix and Gentianae Macrophyllae Radix, belonging to the same genus as Gentianae Radix. These results indicate the necessity to revise the identification test for Gentianae Radix to a more unique method.
Subject(s)
Furaldehyde , Gentiana , Furaldehyde/analogs & derivatives , Furaldehyde/chemistry , Gentiana/chemistry , Japan , Mass Spectrometry , Plant Roots/chemistry , Pharmacopoeias as Topic , Magnetic Resonance Spectroscopy , Chromatography, Liquid , Chromatography, High Pressure Liquid , Drugs, Chinese Herbal/chemistry , East Asian PeopleABSTRACT
Introducción: El bitartrato de epinefrina, también conocido como epinefrina, es un ingrediente farmacéutico importante en el tratamiento de diversas enfermedades, pero su medición precisa es esencial para garantizar la seguridad del medicamento. La Farmacopea de los Estados Unidos (USP) establece los estándares para su análisis, pero la elección del método afecta la precisión de las mediciones. Este estudio investiga cómo los diferentes métodos afectan la medición del bitartrato de epinefrina según las versiones USP-43 y USP-44, que tienen implicaciones significativas para la calidad y la regulación de los medicamentos en el campo. Método: Se eligieron el método volumétrico y el método cromatográfico para comparación. Se utilizaron muestras de epinefrina bitartrato de alta pureza que cumplían con los estándares de la USP-43 y USP-44.Resultados: Los resultados obtenidos por ambos métodos se comparan entre sí y se evalúan según los límites de especificación definidos por USP-43 y USP-44. Los valores obtenidos para algunos parámetros, como la concentración y la pureza del bitartrato de epinefrina, varían considerablemente entre los distintos métodos analíticos. Conclusiones: Este estudio destaca la importancia de una cuidadosa selección del método analítico al evaluar el bitartrato de epinefrina según las directrices USP-43 y USP-44. La elección de la tecnología afecta a los resultados y, por tanto, a la calidad y seguridad de los productos farmacéuticos que contienen esta sustancia. Se recomienda validar el método en cada laboratorio y comparar los resultados con los estándares USP. (AU)
Introduction: Epinephrine bitartrate, also known as epinephrine, is an important pharmaceutical ingredient in the treatment of various diseases, but its accurate measurement is essential to ensure the safety of the drug. The United States Pharmacopeia (USP) sets the standards for its analysis, but the choice of method affects the precision of the measurements. This study investigates how different methods affect the measurements of epinephrine bitartrate based on USP-43 and USP-44, which have significant implications for drug quality and regulation in the field. Method: The volumetric method and chromatographic method were chosen for comparison. High-purity epineph-rine bitartrate samples that met USP-43 and USP-44 standards were used. Results: The results obtained by both methods are compared with and evaluated according to the specification lim-its defined by USP-43 and USP-44. The values obtained for some parameters, such as the concentration and purity of epinephrine tartrate, vary considerably between the different analytical methods. Conclusions: This study highlights the importance of carefully selecting analytical methods when evaluating epi-nephrine tartrate according to USP-43 and USP-44 guidelines. The choice of technology affects the results and, therefore, the quality and safety of the pharmaceutical products containing this substance. It is recommended to validate the method in each laboratory and compare the results with USP standards. (AU)
Subject(s)
Epinephrine/pharmacology , Epinephrine/analysis , Titrimetry , Chromatography , Pharmacopoeias as TopicABSTRACT
A collaborative study was conducted to establish the first Indian Pharmacopoeia Reference Standard (IPRS) for teriparatide to be used in quality control testing of marketed products in compliance with the Indian Pharmacopoeia (IP) monograph. The study objective was to evaluate the candidate standard in terms of the WHO International Standard (IS) to assign its content in mg per vial terms. This study involved four laboratories from India and the candidate standard was calibrated against the WHO IS by each participant laboratory using high-performance liquid chromatography (HPLC) assay method per IP monograph. Direct calibration of the candidate standard resulted in an assigned content of 1.02 mg per vial. Based on the study results the candidate standard was judged suitable to serve as the first IPRS for teriparatide for identification and assay by HPLC.
Subject(s)
Pharmacopoeias as Topic , Reference Standards , Teriparatide , India , Pharmacopoeias as Topic/standards , Humans , Chromatography, High Pressure Liquid/methods , Chromatography, High Pressure Liquid/standards , Quality ControlABSTRACT
Effective information extraction of pharmaceutical texts is of great significance for clinical research. The ancient Chinese medicine text has streamlined sentences and complex semantic relationships, and the textual relationships may exist between heterogeneous entities. The current mainstream relationship extraction model does not take into account the associations between entities and relationships when extracting, resulting in insufficient semantic information to form an effective structured representation. In this paper, we propose a heterogeneous graph neural network relationship extraction model adapted to traditional Chinese medicine (TCM) text. First, the given sentence and predefined relationships are embedded by bidirectional encoder representation from transformers (BERT fine-tuned) word embedding as model input. Second, a heterogeneous graph network is constructed to associate words, phrases, and relationship nodes to obtain the hidden layer representation. Then, in the decoding stage, two-stage subject-object entity identification method is adopted, and the identifier adopts a binary classifier to locate the start and end positions of the TCM entities, identifying all the subject-object entities in the sentence, and finally forming the TCM entity relationship group. Through the experiments on the TCM relationship extraction dataset, the results show that the precision value of the heterogeneous graph neural network embedded with BERT is 86.99% and the F1 value reaches 87.40%, which is improved by 8.83% and 10.21% compared with the relationship extraction models CNN, Bert-CNN, and Graph LSTM.
Subject(s)
Information Storage and Retrieval , Neural Networks, Computer , Pharmacopoeias as Topic , Electric Power Supplies , SemanticsABSTRACT
Con su actual estructura la Farmacopea de los Estados Unidos Mexicanos (FEUM), ha elaborado 35 publicaciones, comenzando por las publicaciones rectoras que son la 5ª. edición en 1988, la 6ª. en 1994, la 7ª en el 2000, la 8ª en el 2004, en el 2008 la 9ª, en el 2011 la 10ª, la 11ª en 2014 y la 12ª en 2018, en 2022 se lanzó la Farmacopea de los Estados Unidos Mexicanos 13ª edición y el suplemento 13.1. en 2023. La Farmacopea Mexicana es una de las más completas del mundo, integrada por la publicación rectora que se dedica a los medicamentos alopáticos, biológicos y biotecnológicos, una publicación especializada en productos naturales, la Farmacopea Herbolaria que en 2021 generó la versión 3.0, la Farmacopea Homeopática, que en 2023 generó la versión 4.0 y el Suplemento para Establecimientos dedicados a la venta y suministro de Medicamentos y demás Insumos para la Salud. Su 1ª edición es de 1998 y explica las actividades del Profesional Farmacéutico en estos Establecimientos. En 2018 se publicó la 6ª edición. Una última publicación, relevante y única en el mundo, es el Suplemento para Dispositivos Médicos. Un Suplemento especializado que cuenta ya con alrededor de las mil quinientas páginas y que en 2023, se publicó la versión 5.0. Complementa a las publicaciones, la generación de alrededor de 100 sustancias de referencia que se utilizan para la verificación del cumplimiento de las monografías Farmacopeicas. En este artículo se presenta el recorrido histórico, de la época prehispánica, posterior a la conquista, posterior a la independencia y de la época actual, así como las modificaciones legales que han permitido alcanzar estos objetivos , bajo el trabajo y supervisión de los profesionales farmacéuticos mexicanos. (AU)
With its current structure, the Pharmacopeia of the United Mexican States (FEUM) has produced 35 publications, beginning with the leading publications, which are the 5th. Edition in 1988, the 6th. In 1994, the 7th in 2000, the 8th in 2004, the 9th in 2008, the 10th in 2011, the 11th in 2014, the 12th in 2018 and in 2022 the 13th edition and in 2023 was launched the supplement 13.1. The Mexican Pharmacopeia is one of the most complete in the world, made up the main publication dedicated to allopathic, biological and biotechnological medicines, additionally an publication specialized in natural products, the Herbal Pharmacopeia that in 2021 published the 3th Edition, the Homeopathic Pharmacopeia, which in 2023 published the 4th Edition, and the Supplement for Establishments dedicated to the sale and supply of Medicines and other Health Supplies. Its 1st Edition is from 1998 and explains the activities of the Pharmaceutical Professional in these Establishments. In 2018 the 6th Edition was published. One last publication, relevant and unique in the world, is the Supplement for medical Devices. A specialized publication that already has around 1500 pages. In 2023 was published the version 5th. Additionally to the different publication, the generation of around 100 reference substances are used to verify the compliance with Pharmacopoeia monographs. This article presents the historical review, from the pre-Hispanic era, after the conquest, after independence and the current years, as well as the legal modifications that have allowed these results to be achieved, under the scientific work and financial supervision of the Mexican pharmaceutical profession. (AU)
Subject(s)
Humans , Pharmacopoeias as Topic , Pharmacists , History , Academies and Institutes , MexicoABSTRACT
The improvement of the harvest period standards is critical in the quality control of Chinese medicinal materials. The present study statistically analyzed the harvest period standards of plant medicinal materials in the 2020 edition of Chinese Pharmacopoeia(Vol.Ⅰ) and put forward the existing problems and suggestions based on herbal records and modern research to provide references for the improvement of the standards. According to the statistical analysis, in 499 types of plant medicinal materials, harvest period standards are recorded under 486 types, accounting for 97.4%, and are lacking in the remaining. Only one medicinal material(Stellariae Radix) is recorded with the standard of the harvest year. The standards of the harvest season and phenological period are recorded under 233 types, accounting for 46.7%. For 237 types, only harvest season is specified, accounting for 47.5%, and for 15 types, only harvest phenological period is specified, accounting for 3.0%. Among 222 types mainly derived from cultivation and 51 types from wild resources and cultivation, only 11 types are recorded with harvest period of cultivated products. Only Stellariae Radix is recorded with the harvest period standards for the wild and cultivated products separately. The harvest period standards of plant medicinal materials with different medicinal parts have certain rules to follow. The main problems about the harvest period standards are discovered. Specifically, no harvest period standards are recorded under 13 types of plant medicinal materials. Almost all perennial cultivated medicinal materials are not recorded with harvest year standard. No phenological period standard is found under 250 types of plant medicinal materials. There is no clear distinction between the harvest period standards of cultivated and wild products. The evidence for harvest period standards of 26 types of plant medicinal materials that can be harvested all year round is insufficient. As a result, it is proposed to strengthen basic research in response to the above-mentioned problems and improve the harvest period standards as soon as possible to ensure the quality of Chinese medicinal materials.
Subject(s)
China , Drugs, Chinese Herbal/standards , Medicine, Chinese Traditional , Pharmacopoeias as Topic , Plants, Medicinal , Quality ControlABSTRACT
ABSTRACT Introduction: In hemodialysis, patients are exposed to a large volume of water, which may lead to fatal risks if not meeting quality standards. This study aimed to validate an alternative method for monitoring microbiological quality of treated water and assess its applicability in dialysis and dialysate analysis, to allow corrective actions in real-time. Methods: Validation and applicability were analyzed by conventional and alternative methods. For validation, E. coli standard endotoxin was diluted with apyrogenic water in five concentrations. For the applicability analysis, treated water for dialysis was collected from different points in the treatment system (reverse osmosis, drainage canalization at the storage tank bottom, reuse, and loop), and dialysate was collected from four machines located in different rooms in the hemodialysis sector. Results: The validation results were in accordance with the Brazilian Pharmacopoeia acceptance criteria, except for the last two concentrations analyzed. In addition, the ruggedness criterion performed under the US Pharmacopoeia was in agreement with the results. Discussion: A limiting factor in the applicability analysis was the absence of the endotoxin maximum permitted level in dialysate by the Brazilian legislation. When comparing the analysis time, the alternative method was more time-consuming than the conventional one. This suggests that the alternative method is effective in the case of few analyses, that is, real-time analyses, favoring corrective actions promptly. On the other hand, it does not support the implementation of the alternative method in a laboratory routine due to the high demand for analyses.
RESUMO Introdução: Na hemodiálise, os pacientes são expostos a um grande volume de água, o que pode levar a riscos fatais se não cumprir com padrões de qualidade. Este estudo teve como objetivo validar um método alternativo para monitorar a qualidade microbiológica da água tratada e avaliar sua aplicabilidade em análises de diálise e dialisato, para permitir ações corretivas em tempo real. Métodos: A validação e aplicabilidade foram analisadas por métodos convencionais e alternativos. Para validação, a endotoxina padrão de E. coli foi diluída com água apirogênica em cinco concentrações. Para a análise de aplicabilidade, a água tratada para diálise foi coletada em diferentes pontos do sistema de tratamento (osmose reversa, canalização de drenagem no fundo do tanque de armazenamento, reutilização e circuito) e o dialisato foi coletado em quatro máquinas localizadas em diferentes salas do setor de hemodiálise. Resultados: Os resultados da validação obedeceram aos critérios de aceitação da Farmacopeia Brasileira, com exceção das duas últimas concentrações analisadas. Além disso, o critério de robustez realizado sob a Farmacopeia dos EUA estava de acordo com os resultados. Discussão: Um fator limitante na análise de aplicabilidade foi a ausência do nível máximo permitido de endotoxina no dialisato pela legislação brasileira. Ao comparar o tempo de análise, o método alternativo consumiu mais tempo que o convencional. Isso sugere que o método alternativo é eficaz no caso de poucas análises, ou seja, análises em tempo real, favorecendo ações corretivas imediatamente. Por outro lado, não suporta a implementação do método alternativo em uma rotina de laboratório devido à alta demanda por análises.
Subject(s)
Humans , Water Quality/standards , Water/adverse effects , Dialysis Solutions/analysis , Renal Dialysis/standards , Pharmacopoeias as Topic , Water Microbiology/standards , Brazil/epidemiology , Water/chemistry , Dialysis Solutions/chemistry , Renal Dialysis/statistics & numerical data , Water Purification/methods , Endotoxins/analysis , Escherichia coli/growth & developmentABSTRACT
La contribución de Teophilus Redwood tanto a la Farmacopea Británica como a la Farmacia Práctica son perfiladas en esta parte del trabajo. El galés Redwood es uno de los héroes de la farmacia británica, y la Escuela de Farmacia de la Universidad de Cardiff lleva su nombre: Edificio Redwood. Se consideran los comienzos de la "Pharmaceutical Society" y de la "Chemical Society", ambas fundadas el mismo año, en 1841. La fundación de ambas instituciones fue un hecho decisivo en el establecimiento de la farmacia y la química como disciplinas académicas distintivas. Seis de los veintitrés miembros honorarios elegidos por la "Pharmaceutical Society" en 1841, se encontraban entre los fundadores de la "Chemical Society". Redwood ocupó durante unos veinte años seguidos puestos directivos en la "Chemical Society": miembro del Consejo (1849-50), Secretario (1851-65), Tesorero (1865-69) y Vicepresidente (1869-72). Se ofrece un breve resumen de los Congresos Internacionales de Farmacia. Redwood fue Presidente del 5º Congreso internacional de Farmacia, celebrado en Londres, que puede considerarse como una de las etapas previas en la creación de la Federación Farmacéutica Internacional (FIP)
Theophilus Redwood contribution to both the British Pharmacopeia and Practical Pharmacy are outlined in this part of the paper. The Welsh Redwood is one of the heroes of the British pharmacy and the building of the School of Pharmacy of the University of Cardiff takes his name: Redwood building. The beginnings of the Pharmaceutical Society and Chemical Society, both institutions founded in the same year, 1841, are outlined. The founding of both was a decisive event in the establishment of pharmacy and chemistry as distinctive academic disciplines. Six of the twenty-three honorary members elected by the Pharmaceutical Society in 1841 were among the founders of the Chemical Society. Redwood held executive positions in the Chemical Society for twenty consecutive years: Council member (1849-50), Secretary (1851-65), Treasurer (1865-69) and Vicepresident (1869-72). An overview of the International Congresses of Pharmacy is given. Redwood was President of the fifth International Congress of Pharmacy celebrated in London, one of the stages in the creation of the International Pharmaceutical Federation (FIP)
Subject(s)
Humans , History, 19th Century , History of Pharmacy , Pharmacopoeias as Topic/history , England , Pharmacists , Societies, PharmaceuticalABSTRACT
To clarify the change and development of original plants of " Manjingzi"( Viticis Fructus),a traditional Chinese medicine,we investigated Vitex species on the ancient Chinese herbal texts. The study concluded that the Vitex trifolia and V. trifolia var.simplicifolia included in the Chinese Pharmacopoeia( 2015 edition) are only two sources of ancient medicinal Viticis Fructus. There are many sources of vines used in ancient times,which are not fixed and unified. The early use of Viticis Fructus is likely to be the V. quinate var. quinata,V. negundo var. cannabifolia and V. negundo var. negundo. From the Tang Dynasty,the use of V. trifolia var. simplicifolia has been appeared. Until Li Shizhen of the Ming Dynasty,the V. trifolia has been used as a source of medicine for the Viticis Fructus,but even so,the source of medicinal plants of Viticis Fructus has not been unified. We suggested V. trifolia var. simplicifolia be used as mainly species for " Manjingzi" due to its widely used in ancient China.
Subject(s)
China , Drugs, Chinese Herbal/history , Fruit , History, 15th Century , History, Medieval , Medicine, Chinese Traditional , Pharmacopoeias as Topic , Plants, Medicinal , VitexABSTRACT
En este trabajo se pasa revista a los primeros textos publicados sobre análisis volumétrico aportando datos sobre la vida y obra de sus autores: Schwarz, Mohr, Poggiale, y Beckurts
This paper reviews the first published textbooks on volumetric analysis providing data on the life and work of their authors: Schwarz, Mohr, Poggiale and Beckurts